The University of Alabama at Birmingham (UAB) was awarded a $1,317,584 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from July 1, 2025 to June 30, 2028, will support UAB's research on "Macrophage-Centric Prognostic Biomarkers for Checkpoint Blockade Immunotherapy in Melanoma." The project aims to develop innovative prognostic biomarkers and advance the...
The University of Alabama at Birmingham (UAB) was awarded a $733,662 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, supports research to investigate the role of tumor glycans in immune suppression. This federally funded project aims to advance scientific understanding of how specific carbohydrate molecules on tumor cells can inhibit the body's immune response, with the goal of...
This federal Project Grant award of $227,167.00, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research at the University of Alabama at Birmingham (UAB) focused on developing macrophage-centric prognostic biomarkers for checkpoint blockade immunotherapy in melanoma. The award, with a performance period from July 1, 2025 to June 30, 2028, will enable UAB researchers to explore innovative approaches to...
The University of Alabama at Birmingham (UAB) was awarded a $1,485,000.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to improve the oncolytic immunovirotherapy of malignant glioma by targeting the glioma secretome. The 3-year grant was awarded on September 30, 2023 and is set to conclude on September 29, 2026. UAB is a public research university known for its innovative and interdisciplinary approach to education, and it...
The University of Alabama at Birmingham (UAB) received a $1,599,981.00 Project Grant award from the Defense Health Agency on June 1, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to activate immune reserves and prevent secondary bacterial lung infections after trauma and hemorrhage. This biomedical research project aims to improve health outcomes for military service members and the broader public. The project will be conducted over a...
The University of Alabama at Birmingham (UAB) has been awarded a $740,075 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "PADI4 as a Driver and Therapeutic Target for Uveal Melanoma Therapy". The award, which runs from September 1, 2024 to August 31, 2027, will support UAB's research into novel therapeutic approaches for treating uveal melanoma, an aggressive form of eye cancer. As a leading research...
The University of Alabama at Birmingham (UAB) received a $1,139,184.00 Project Grant award from the Defense Health Agency for the research project "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA". The award, which began on August 15, 2023 and is scheduled for completion on August 14, 2027, is funded through the Military Medical Research and Development program (CFDA 12.420). This grant supports UAB's biomedical research efforts to transform health care for Service...
The University of Alabama at Birmingham (UAB) was awarded a $2,069,849 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support UAB's research from May 1, 2023 to April 30, 2027 to understand cardiovascular disease in mental health and stress disorders. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research,...
The University of Alabama at Birmingham (UAB) has been awarded a $297,000 Project Grant from the Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This grant, awarded on August 1, 2024, will fund research to evaluate the role of Notch signaling in chronic pancreatitis. As a leading research institution, UAB will leverage its expertise in biomedical research to advance scientific understanding and potentially improve treatment...
The University of Alabama at Birmingham (UAB) was awarded a $1,361,285 Phase 1/2 clinical trial grant by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a trial of the MEK inhibitor mirdametinib and TYK2 inhibitor deucravacitinib for advanced malignant peripheral nerve sheath tumors. This federally funded research project aims to advance innovative medical treatments and technologies to...